GlassScriptPhysician profile
Anwar D Mire
NPI 1508868969
$4,098.91
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $341 · 2021: $592 · 2022: $929 · 2023: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.78 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $407.75 | 2019-2023 | Farxiga, Fasenra |
| Novo Nordisk INC | $360.51 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $331.55 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.43 | 2019-2023 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.93 | 2019-2023 | Xifaxan |
| Pfizer INC. | $263.57 | 2019-2023 | |
| Amgen INC. | $258.84 | 2019-2023 | Evenity, Prolia, Otezla |
| Allergan, INC. | $179.29 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $168.77 | 2019-2023 | |
| Lilly USA, LLC | $115.53 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $109.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $89.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.35 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $86.52 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $73.29 | 2021-2023 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $66.15 | 2019-2022 | |
| Astellas Pharma US INC | $61.95 | 2022 | |
| Amarin Pharma, INC. | $55.46 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $45.12 | 2022 | |
| Ironwood Pharmaceuticals, INC | $35.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.76 | 2020-2021 | |
| Zyla Life Sciences, INC. | $29.02 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.52 | 2023 | Horizant |
| Almatica Pharma LLC | $18.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2022 | |
| Eisai INC. | $14.56 | 2021 | |
| Daiichi Sankyo INC. | $13.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.91 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Mire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.